Biotech | February 27, 2022
New data reinforces efficacy of Tezspire
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Zydus unveils its ‘innovation and care’ centric corporate brand identity
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Recall does not include any metabolic deficiency nutrition formulas
Subscribe To Our Newsletter & Stay Updated
